Xiumei Peng1,2, Xiaoliang Liu3, Long Xu4, Yuemin Li1,5, Huaiqing Wang5,6, Lele Song1,5,7, Wenhua Xiao1,2. 1. The Chinese PLA Medical College and the Chinese PLA General Hospital, Beijing 100853, China. 2. Department of Oncology, the Fourth Medical Center of the Chinese PLA General Hospital, Beijing 100037, China. 3. Department of Radiotherapy, the Chinese PLA General Hospital, Beijing 100853, China. 4. Department of Oncology, the General Hospital of the Chinese PLA Northern Theater Command, Shenyang 110016, China. 5. Department of Radiotherapy, the Eighth Medical Center of the Chinese PLA General Hospital, Beijing 100091, China. 6. Department of Graduate, Hebei North University, Zhangjiakou 075000, China. 7. BioChain (Beijing) Science and Technology, Inc., Beijing 100176, China.
Abstract
BACKGROUND: Instant monitoring of the therapeutic effect of systematic therapy in late-stage lung cancer is crucial for response assessment and strategy adjustment. Previous study found that specific plasma methylation markers may be applied to therapeutic effect assessment. In order to investigate the performance of plasma mSHOX2 in assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer, we performed the study focusing on patients underwent chemotherapy or tyrosine kinase inhibitor (TKI)-based targeted therapy. METHODS: Blood samples from 163 subjects, including 30 stage I, 29 stage II, 26 stage III and 68 stage IV lung cancer patients, were recruited in this study. Quantitative relationship between primary tumor size and the plasma mSHOX2 level was established. Blood samples before therapy and two cycles after therapy were obtained from 68 stage IV patients, and the mSHOX2 level was quantified as ΔΔCt. RESULTS: Sharp decrease of plasma mSHOX2 level was seen in patients with partial response (PR) while not in those with stable disease (SD). The plasma mSHOX2 level change reflected the degree of response and correlated with the maximal diameter of primary tumors in linear relationship. The mSHOX2 levels before and two cycles after therapy were predictors of the overall survival, while the mSHOX2 level change or the tumor size change were not predictors of the overall survival. Furthermore, univariable and multivariable Cox regression revealed that mSHOX2 level before therapy was the only independent predictor of the overall survival with a hazard ratio of 1.414. CONCLUSIONS: mSHOX2 is effective for therapeutic effect assessment and prognosis prediction of stage IV lung cancer patients underwent systematic therapy.
BACKGROUND: Instant monitoring of the therapeutic effect of systematic therapy in late-stage lung cancer is crucial for response assessment and strategy adjustment. Previous study found that specific plasma methylation markers may be applied to therapeutic effect assessment. In order to investigate the performance of plasma mSHOX2 in assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer, we performed the study focusing on patients underwent chemotherapy or tyrosine kinase inhibitor (TKI)-based targeted therapy. METHODS: Blood samples from 163 subjects, including 30 stage I, 29 stage II, 26 stage III and 68 stage IV lung cancer patients, were recruited in this study. Quantitative relationship between primary tumor size and the plasma mSHOX2 level was established. Blood samples before therapy and two cycles after therapy were obtained from 68 stage IV patients, and the mSHOX2 level was quantified as ΔΔCt. RESULTS: Sharp decrease of plasma mSHOX2 level was seen in patients with partial response (PR) while not in those with stable disease (SD). The plasma mSHOX2 level change reflected the degree of response and correlated with the maximal diameter of primary tumors in linear relationship. The mSHOX2 levels before and two cycles after therapy were predictors of the overall survival, while the mSHOX2 level change or the tumor size change were not predictors of the overall survival. Furthermore, univariable and multivariable Cox regression revealed that mSHOX2 level before therapy was the only independent predictor of the overall survival with a hazard ratio of 1.414. CONCLUSIONS: mSHOX2 is effective for therapeutic effect assessment and prognosis prediction of stage IV lung cancer patients underwent systematic therapy.
Authors: K Darwiche; P Zarogoulidis; K Baehner; S Welter; R Tetzner; J Wohlschlaeger; D Theegarten; T Nakajima; L Freitag Journal: Ann Oncol Date: 2013-09-11 Impact factor: 32.976
Authors: Dimo Dietrich; Christoph Kneip; Olaide Raji; Triantafillos Liloglou; Anke Seegebarth; Thomas Schlegel; Nadja Flemming; Sebastian Rausch; Jürgen Distler; Michael Fleischhacker; Bernd Schmidt; Thomas Giles; Martin Walshaw; Chris Warburton; Volker Liebenberg; John K Field Journal: Int J Oncol Date: 2011-11-16 Impact factor: 5.650
Authors: Christoph Kneip; Bernd Schmidt; Anke Seegebarth; Sabine Weickmann; Michael Fleischhacker; Volker Liebenberg; John K Field; Dimo Dietrich Journal: J Thorac Oncol Date: 2011-10 Impact factor: 15.609
Authors: Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum Journal: N Engl J Med Date: 2013-05-23 Impact factor: 91.245
Authors: Peter Ilse; Stefan Biesterfeld; Natalia Pomjanski; Christian Fink; Martin Schramm Journal: Cancer Genomics Proteomics Date: 2013 Sep-Oct Impact factor: 4.069
Authors: Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field Journal: BMC Cancer Date: 2010-11-03 Impact factor: 4.430
Authors: Katja U Schneider; Dimo Dietrich; Michael Fleischhacker; Gunda Leschber; Johannes Merk; Frank Schäper; Henk R Stapert; Erik R Vossenaar; Sabine Weickmann; Volker Liebenberg; Christoph Kneip; Anke Seegebarth; Fikret Erdogan; Gudrun Rappold; Bernd Schmidt Journal: BMC Cancer Date: 2011-03-22 Impact factor: 4.430
Authors: Dimo Dietrich; Maria Jung; Svenja Puetzer; Annette Leisse; Emily Eva Holmes; Sebastian Meller; Barbara Uhl; Philipp Schatz; Claudia Ivascu; Glen Kristiansen Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Sara Witting Christensen Wen; Rikke Fredslund Andersen; Torben Frøstrup Hansen; Christa Haugaard Nyhus; Henrik Hager; Ole Hilberg; Anders Jakobsen Journal: Transl Lung Cancer Res Date: 2021-02